首页> 外文期刊>AIDS Research and Human Retroviruses >Transmission of drug-resistant HIV type 1 strains in HAART-naive patients: a 5-year retrospective study in Sicily, Italy.
【24h】

Transmission of drug-resistant HIV type 1 strains in HAART-naive patients: a 5-year retrospective study in Sicily, Italy.

机译:初治HAART的患者中耐药HIV 1型毒株的传播:一项在意大利西西里岛进行的为期5年的回顾性研究。

获取原文
获取原文并翻译 | 示例
           

摘要

The transmission of drug-resistant HIV-1 strains might compromise the efficacy of current first-line antiretroviral (ARV) regimens. Between 2004 and 2008, HIV-1 reverse transcriptase (RT) and protease (PR) genes of 108 ARV-naive Sicilian patients were amplified and sequenced to describe the prevalence of ARV resistance mutations among HAART-naive HIV-1-infected individuals. The frequency of transmitted drug resistance mutations (DRAMs) was determined by using genotypic interpretation algorithms. The proportion of HAART-naive HIV-1-infected patients in Sicily increased from 18.4% to 23.5% during 2004-2008. Among naive patients, the overall prevalence of DRAMs was 15.7% [17/108; 95% CI: 9.4-24.0]. DRAMs to nonnucleoside reverse transcriptase inhibitors (nNRTI) were detected most frequently [11/108 (10.2%)], of which K103N was the most prevalent (4.6%), whereas the prevalence of DRAMs was lowest for protease inhibitors (PI) [3/108 (2.8%)]. Drug resistance substitutions associated with two or three drug classes were rarely observed. The prevalence of HIV-1 DRAMs in Sicily was relatively higher than that observed in Italy and other European geographic areas and much higher than in resource-limited countries. However, the possible clinical role played by DRAMs in HAART-naive HIV-1-infected individuals will require further assessment.
机译:耐药HIV-1菌株的传播可能会损害当前的一线抗逆转录病毒(ARV)方案的疗效。在2004年至2008年之间,对108例ARV初次感染的西西里患者的HIV-1逆转录酶(RT)和蛋白酶(PR)基因进行了扩增和测序,以描述HAART初次感染HIV-1的患者中ARV耐药突变的发生率。通过使用基因型解释算法确定了传播的耐药性突变(DRAM)的频率。 2004年至2008年期间,在西西里岛接受HAART的未感染HIV-1的患者比例从18.4%增加到23.5%。在天真的患者中,DRAM的总患病率为15.7%[17/108; 95%CI:9.4-24.0]。 DRAM较非核苷类逆转录酶抑制剂(nNRTI)检出率最高[11/108(10.2%)],其中K103N最为流行(4.6%),而蛋白酶抑制剂(PI)的DRAM患病率最低[3]。 / 108(2.8%)]。很少观察到与两种或三种药物类别相关的耐药性替代。西西里岛的HIV-1 DRAM患病率相对高于意大利和其他欧洲地理区域,并且远高于资源有限的国家。但是,DRAMs在未感染HAART的HIV-1感染者中可能发挥的临床作用需要进一步评估。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号